Moderna, Inc. (MRNA)
Stock Price Chart
Key Info
| Market Cap | 27.39B |
| Revenue (ttm) | 105.84M |
| Net Income (ttm) | -487.25M |
| Shares Out | 394.59M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | 20.16 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 27, 2020 |
| Last Price | $69.41 |
| Previous Close | $70.24 |
| Change ($) | -0.83 |
| Change (%) | -1.18% |
| Day's Open | 70.45 |
| Day's Range | 68.81 - 71.35 |
| Day's Volume | 1,390,197 |
| 52-Week Range | 15.52 - 95.21 |
More Stats
| Market Cap | 27.39B |
| Enterprise Value | 24.84B |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 394.59M |
| Float | 322.40M |
| EPS (basic) | -1.39 |
| EPS (diluted) | -1.39 |
| FCF / Share | -0.98 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 28.22M |
| Short Ratio | 3.02 |
| Short % of Float | 8.75% |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | 20.16 |
| P/FCF Ratio | n/a |
| PS Ratio | 258.77 |
| PB Ratio | 9.44 |
| Revenue | 105.84M |
| Operating Income | -512.94M |
| Net Income | -487.25M |
| Free Cash Flow | -371.12M |
| Net Cash | 2.55B |
| Net Cash / Share | 6.46 |
| Gross Margin | -412.03% |
| Operating Margin | -484.63% |
| Profit Margin | -460.40% |
| FCF Margin | -350.63% |
| ROA | -12.41% |
| ROE | -22.75% |
| ROIC | -32.20% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | 60.21 | 135 | 206 | 108 |
| Revenue Growth | -55.42% | -34.38% | 89.88% | - |
| Gross Profit | 60.21 | 135 | 206 | 108 |
| Operating Income | -546 | -413 | -269 | -224 |
| Net Income | -514 | -385 | -256 | -216 |
| Shares Outstanding | 331 | 81.11 | 64.50 | 60.75 |
| Earnings Per Share | -1.55 | -4.95 | -4.18 | -3.79 |
| Operating Cash Flow | -459 | -331 | -331 | 66.73 |
| Capital Expenditures | -31.55 | -106 | -58.40 | -33.14 |
| Free Cash Flow | -491 | -437 | -390 | 33.59 |
| Cash & Equivalents | 1,104 | 1,522 | 757 | 1,058 |
| Total Debt | 132 | 33.49 | 15.69 | 12.50 |
| Net Cash / Debt | 972 | 1,489 | 741 | 1,046 |
| Assets | 1,589 | 1,962 | 1,084 | 1,417 |
| Liabilities | 415 | 432 | 459 | 575 |
| Book Value | 1,175 | 1,530 | -551 | -335 |
Company Profile
Company Details
| Full Name | Moderna, Inc. |
| Country | United States |
| Employees | 975 |
| CEO | Stéphane Bancel |
Stock Information
| Ticker Symbol | MRNA |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: MRNA |
| IPO Date | December 7, 2018 |
Description
Moderna, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.